Use of umbilical cord blood (CB) for stem cell transplantation has a number of advantages, but a major disadvantage is the relatively low cell number available. Ex vivo cell expansion has been proposed to overcome this limitation, and this study therefore evaluated the use of perfusion culture systems for CB cell expansion. CB was cryopreserved using standard methods and the thawed unpurified cells were used to initiate small-scale cultures supplemented with PIXY321, flt-3 ligand, and erythropoietin in serum-containing medium. Twelve days of culture resulted in the optimal output from most CB samples. Frequent medium exchange led to significant increases in cell (93%), CFU-GM (82%) and LTC-IC (350%) output as compared with unfed cultures. As the inoculum density was increased from 7.5 ؋ 
Human umbilical cord blood (CB) is known to contain long-term repopulating hematopoietic stem cells, as evidenced by successful CB transplantation after high-dose chemotherapy.
1-3 CB transplants have been performed for various malignant and non-malignant clinical indications where no suitably matched donor was available. The use of CB for stem cell transplantation has a number of advantages including widespread availability and reduced graftversus-host disease, 4 as well as the potential to provide a tumor-free cell source to replace current autologous cell transplantation therapies. However, a major disadvantage is the relatively low cell number available, which is believed to contribute to delayed engraftment in CB transplantation as compared with bone marrow (BM) or mobilized peripheral blood (mPB) transplantation. For example, a recent CB study showed recovery to 500 ANC and 20 000 platelets per mm 3 required 22 and 56 days, respectively, even with G-CSF support in the post-transplant setting. 3 The time to engraftment has been reported to be inversely related to the cell dose given, suggesting that the availability of more cells, or certain cell types, might lead to accelerated engraftment. 3, 5 Further, because of the low cell number, the adequacy of CB samples for adult transplantation is uncertain. 6, 7 Unlike BM or mPB, where the collection of more cells is relatively straightforward, the number of cells available from a CB donor is fixed. Therefore, increasing the number of stem and progenitor cells in a CB sample is of great interest.
A number of laboratory studies have shown that CB cells can be expanded ex vivo using methods similar to those employed for the expansion of BM or mPB cells. In fact, many studies have suggested that CB contains a more primitive cell population, having more in vitro and in vivo proliferative potential than BM or mPB cells, [8] [9] [10] [11] [12] [13] [14] [15] making them a prime target for ex vivo expansion therapy or gene therapy procedures. Most of the recent literature on CB cell expansion has focused on the culture of CD34-enriched cells or subsets thereof. However, perfusion bioreactor systems have been proven capable of expanding non-enriched cells from BM [16] [17] [18] and mPB, 19 due to their ability to support high density accessory cell populations. 17, 20 In fact, in the CB transplant setting, the potential advantages of CD34-enrichment prior to expansion, such as tumor purging and T cell depletion, are less relevant. The ability to expand cells without CD34-enrichment would therefore provide an advantage, because considerable processing effort, cost and cell loss could be avoided. 16, 21 Although perfusion culture parameters for BM cell expansion have been extensively optimized 17, 20, 22, 23 and clinically tested, [24] [25] [26] potential differences between CB and BM cells warrant the study of several culture parameters for CB cell expansion within the perfused culture environment. In addition, the likely clinical use of cryopreserved and banked CB samples dictates the study of thawed cells in such culture systems. A series of small-scale optimization studies was therefore undertaken, and led to the selection of conditions for clinical-scale expansion of CB cells in a novel automated perfusion cell culture system, with the ultimate goal of generating expanded CB cells under cGMP requirements for the treatment of patients undergoing CB transplantation.
Materials and methods

Cell culture medium
Long-term culture (LTC) medium was prepared by supplementing Iscove's modified Dulbecco's medium (IMDM) with 10% horse serum, 10% fetal bovine serum (FBS), 4 mm l-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (all from Gibco, Grand Island, NY, USA), and 5 m hydrocortisone (Sigma, St Louis, MO, USA). In some experiments, serum-free media were compared with the serum-containing LTC medium. StemPro-34 (Gibco) was supplemented with glutamine and antibiotics, and X-VIVO 15 (Biowhittaker, Walkersville, MD, USA) was supplemented with hydrocortisone, in accordance with the manufacturers' directions. All media for expansion culture were supplemented with a previously optimized combination of 5 ng/ml PIXY321 (Immunex, Seattle, WA, USA), 0.1 U/ml erythropoietin (Epo; Amgen, Thousand Oaks, CA, USA), and 25 ng/ml flt-3 ligand (FL; Immunex) as described. 17, 27 Cell source and cryopreservation procedure Human umbilical cords were obtained after vaginal delivery of full-term newborns (St Joseph Mercy Hospital, Ann Arbor, MI, USA). CB was drawn from the clamped and cannulated umbilical cord vein, and then placed into a polypropylene container containing ACD anticoagulant (Baxter, Deerfield, IL, USA). Within 8 h at ambient temperture, the samples were received and processed for cryopreservation. A small sample of unmanipulated cells was first removed for cell counts (Coulter, Hialeah, FL, USA) and assays. CB was slowly mixed 1:5 with a solution of 50% DMSO (Research Industries, Midvale, UT, USA), 200 g/ml DNase (Sigma), and 5% dextran (Sigma) in 0.9% saline (Abbott, North Chicago, IL, USA) on ice as previously described. 4 Alternatively, Hespan (DuPont Merck Pharmaceuticals, Wilmington, DE, USA) was added to CB 1:5 to give a 1.2% concentration, and cells were centrifuged at 50 g for 10 min to deplete erythrocytes. 28 The low density cells were resuspended in LTC medium and were then mixed with DMSO solution as above. Once processed by one of these two methods, CB cell suspensions were placed in 250 ml cryopreservation bags (Baxter) and subjected to rate-controlled freezing (Forma Scientific, Marietta, OH, USA). Starting at 4°C, the freezing chamber was cooled at 1°C per min to Ϫ6°C, at 25°C per min to Ϫ55°C to quickly remove the latent heat of fusion, warmed at 15°C per min to Ϫ14°C to continue solid phase cooling, and then cooled at 1°C per min to Ϫ45°C and at 10°C per min to Ϫ90°C, after which bags were transferred into liquid N 2 storage. Cells were later thawed by placing in a 37°C water bath for 1 min, and were then diluted 1:1 with a solution of 2.5% human serum albumin (Michigan Dept of Public Health, Lansing, MI, USA) and 5% dextran in saline as previously described. 4 Cells were then centrifuged and resuspended in LTC medium.
Small-scale cell culture system
Cells were cultured at various densities in 24 well plates (Costar, Cambridge, MA, USA) in 0.6 ml of growth medium using frequent manual medium exchange. 17, 20, 29 Inoculum densities were adjusted by the measured cell viability after thawing. All density measurements are expressed per unit area (cm 2 ) rather than per unit volume in order to facilitate direct comparisons between the smallscale and clinical-scale systems. After inoculation, 50% of the culture volume was replaced on various days to deliver a rate of 0% (no feeding), 200% (fed on days 5, 8, 10 and 11), 250% (fed on days 4, 7, 9, 10 and 11), or 350% (fed on days 3, 5, 7, 8, 9, 10 and 11) volume medium exchange over 12 days of culture. Cells removed in the spent medium at each feeding were resuspended in fresh medium and returned to the wells. Cells were harvested after 1 to 14 days of culture using trypsinization as previously described, 17 and were then washed and resuspended in LTC medium for counting and assays.
Clinical-scale automated cell production system (CPS)
The CPS (Aastrom Biosciences, Ann Arbor, MI, USA) embodies a modular, closed-system process comprised of a pre-sterilized, single-use disposable cell cassette operated by automated, microprocessor-controlled instruments. 30 The instrumentation components of the system include an incubator unit and processor unit, along with a computerbased monitor. The cell cassette provides a functionally closed, sterile environment in which cell production occurs. The sterile fluid pathway contained in the cell cassette includes the cell growth chamber, a container for medium supply, a pump mechanism for delivery of medium to the growth chamber, a container for the collection of waste medium exiting the growth chamber, a container for the collection of harvested cells, interconnected tubing between the components, and sterile barrier elements to protect the culture from contamination.
A dedicated small incubator controls the physical environment and operations of each cell cassette. The incubator receives and self-engages the disposable cell cassette, and then controls the flow of medium to the growth chamber, the temperature (4°C) of the growth medium supply compartment, the temperature (37°C) of the growth chamber compartment, and the concentration (5% CO 2 in air) and flow rate (6 ml/min) of gases delivered to the gas side of the culture chamber.
The processor performs the initial priming of the cell cassette with growth medium and the controlled inoculation and distribution of cells. The same unit also performs the removal (harvest) of cells from the growth chamber at the completion of the cell production process, transferring the cells to a pre-attached harvest container (blood transfusion bag) in a sterile manner. The heart of the processor is a mechanical platform which provides the cell cassette with automated tilting motions and valve actuations necessary to achieve priming and even distribution of cells, and for harvest of cells. The automated system design provides for a high level of sterility assurance during each procedure by replacing the need for operator manipulation of culture devices within a laminar air flow hood, and is specifically designed for production of patient-specific cells.
Flow cytometry analysis
Cells to be analyzed were washed and resuspended in phosphate buffered saline (PBS; Gibco) containing 1% bovine serum albumin (BSA; Intergen, Purchase, NY, USA). Mature erythrocytes were lysed with 0.16 m ammonium chloride solution (Sigma). Tubes containing 10 6 cells in 0.5 ml were stained on ice with various combinations of fluorescently conjugated monoclonal antibodies. T and B lymphocytes were assessed by staining with FITC-Leu4 (anti-CD3; Becton Dickinson, San Jose, CA, USA) and PELeu12 (anti-CD19; Becton Dickinson), respectively. Leukocytes and erythrocytes were assessed by staining with PerCP-Hle-1 (anti-CD45; Becton-Dickinson) and FITCanti-glycophorin A (Dako, Carpinteria, CA, USA), respectively. Viability was determined by propidium iodide (Molecular Probes, Eugene, OR, USA) staining. After 10 min, cells were washed and resuspended in 0.5 ml PBS/BSA for analysis on a FACS Vantage flow cytometer (Becton Dickinson).
Methylcellulose colony assays
Cells were inoculated in colony assay medium containing 0.9% methylcellulose (Sigma), 30% FBS, 1% BSA, 100 m 2-mercaptoethanol (Sigma), 2 mm l-glutamine (Gibco), 5 ng/ml PIXY321, 5 ng/ml G-CSF (Amgen), and 10 U/ml Epo. Cells were plated at 1500 to 20 000 per ml, depending upon the expected clonogenicity. Cultures were maintained for 14 days and were then scored as previously described. 17 
Long-term culture-initiating cell (LTC-IC) assays
LTC-IC were determined by limiting dilution analysis (LDA) on irradiated pre-formed stroma using a modification 23 of a previously described technique. 31 Briefly, stroma was prepared as described 17 in 96-well plates at 10 4 cells per well in 100 l LTC medium. Test cells were then added to these stromal layers at four concentrations in 100 l LTC medium per well (20 replicates each). Thawed CB cells were plated at 2.5, 5, 10 and 20 thousand per well, and expanded cells were plated at 7.5, 15, 30 and 60 thousand per well. The plates were then placed at 33°C in a fully humidified atmosphere of 5% CO 2 in air, and the cultures were fed weekly by replacing 100 l LTC medium per well. At week 5, cells were harvested from each well as previously described. 23 The cells from each well were added directly to 0.25 ml of colony assay medium in nontissue culture treated 24-well plates (Falcon, Lincoln Park, NJ, USA). After 14 days, wells were scored for colonies as described above. For each sample, the number of LTC-IC was determined through an iterative calculation procedure 32 based on the maximum likelihood method. 33 
Analysis of endogenous growth factor mRNA by RT-PCR
The presence of transcripts encoding several hematopoietic growth factors was assessed in both BM and CB expansion cultures performed under identical conditions using an inoculum density of 3 ϫ 10 5 nucleated cells per cm 2 with the 250% volume medium exchange protocol. Total RNA was isolated from parallel wells on different days of culture using the RNeasy total RNA isolation kit (Qiagen, Santa Clarita, CA, USA). cDNA was generated from 1 g of total RNA using 200 U of MMLV reverse transcriptase (RT; Gibco) in 20 l reactions containing 50 pmol oligo(dT), 1 mm each dNTP, 20 U RNasin RNase-inhibitor (Promega, Madison, WI, USA), 10 mm Tris-HCl pH 8.3, 50 mm KCl, and 5 mm MgCl 2 . Reactions were incubated for 10 min at room temperature, followed by a 45 min incubation at 37°C and 5 min at 95°C. PCR amplification was performed on 2 l of each RT reaction using 1 U Taq DNA polymerase in 25 l reactions containing 200 m dNTP, 25 pmol sense primer, 25 pmol antisense primer, 10 mm Tris-HCl pH 8.3, 50 mm KCl, and 1.5 mM MgCl 2 . The sequences of sense and antisense primers used to detect transcripts for each hematopoietic growth factor are listed in Table 1 . PCR amplification was performed in a GeneAmp PCR System (Perkin-Elmer, Foster City, CA, USA) with 35 cycles consisting of 30 s denaturation at 95°C, 30 s anneal at 62°C, and 1 min extension at 72°C followed by a single 7 min extension at 72°C. Reactions amplifying GM-CSF, IL-11, and Tpo sequences underwent a second round of amplification for an additional 25 cycles using 1 l of a 1:100 dilution of the initial reaction as starting material. PCR products were electrophoresed on a 2% agarose gel and visualized by ethidium bromide staining.
Results
Effect of inoculum density
In clinical practice, the number of CB cells available for ex vivo expansion will likely vary from donor to donor. Therefore, initial experiments evaluated the effect of inoculum density in 24-well plates with frequent medium exchange over a 12 day culture. Seven cryopreserved and thawed CB samples were used to initiate cultures with dif- ferent inoculum densities of viable nucleated cells. As the inoculum density was increased from 7.5 ϫ 10 4 per cm 2 to 6.0 ϫ 10 5 per cm 2 , the culture output of cells, CFU-GM, and LTC-IC increased (Figure 1 ). Cell and CFU-GM output generally reached a plateau at 6.0 ϫ 10 5 per cm 2 and did not significantly increase further as the inoculum density was increased to 1.2 ϫ 10 6 per cm 2 , whereas LTC-IC output appeared to increase further. Because the increase in culture output did not increase linearly with the increasing inoculum density, the cell and CFU-GM expansion ratios were highest at the inoculum density of 1. 
Effect of feeding interval
In the optimization of BM MNC expansion, one of the most critical interactions between culture parameters was shown to be that between inoculum density and perfusion rate. 20 Therefore, the effect of different perfusion rates was evaluated in cultures with different CB cell inoculum densities. Frequent medium exchange led to a significant increase in the output of cells (93%), CFU-GM (82%), and LTC-IC (350%) as compared with unfed cultures (Figure 3) . However, the cultures were not particularly sensitive to variations in feeding rate within the range of 200 to 350% volume medium exchange. This was true even with culture inoculum densities ranging from 1.5 ϫ 10 5 per cm 2 to 1.2 ϫ 10 6 per cm 2 , a result significantly different from that found with BM. 20 
Effect of culture duration
Because CB cells are more prolific than BM cells, it is possible that a shorter culture duration is warranted. Conversely, because CB cells are more primitive than BM cells, it may be that a longer culture period is required to allow them to reach an optimal growth stage. Therefore, the duration of expansion was evaluated as a culture variable. Replicate cultures were initiated at 3 ϫ 10 5 per cm 2 and fed with the 250% exchange protocol with harvest at various times thereafter for cell analysis. The kinetics of CB cell expansion were measured in eight experiments (Figure 4) . The results show that cell numbers increased to day 14 in every experiment. CFU-GM numbers increased to day 10 in all experiments, to day 12 in most experiments, and from day 12 to day 14 in some experiments. Significant differences in LTC-IC numbers on different days of culture were not apparent, suggesting that LTC-IC were not being Effect of viable nucleated cell inoculum density on cord blood cell expansion culture output. Thawed cord blood cells from seven donors were inoculated at various densities (per cm 2 ) in parallel triplicate cultures, and the output of (a) cells, (b) CFU-GM, and (c) LTC-IC were determined. The output from each donor is shown with a different symbol that is used throughout Figures 1, 2 and 4. depleted as the cultures progressed. Interestingly, the kinetics of expansion were not significantly affected by changes in inoculum density or feeding rate within the ranges tested here (not shown). Because 12 days of culture appeared to give the most optimal culture output from the majority of donors, subsequent experiments focused on 12-day culture duration. 
Flow cytometric analysis of expansion
During the expansion period, the cellular composition of the culture changed dramatically, as evidenced by the significant enrichment of CFU-GM progenitors. To gain further insight into the changes in cellular composition, flow cytometry was used to assess the appearance and disappearance of different cell populations during the culture period. The percentage of viable cells increased quickly to above 98% (Figure 5a ), whereas the percentage of both T and B lymphocytes declined exponentially (Figure 5b ). Leukocytes (CD45 ϩ ) increased in frequency, whereas erythroid cells (glyA ϩ ) declined in frequency.
Use of serum-free media
We have previously found a number of serum-free media to be inadequate for the support of perfused BM MNC cultures, particularly with respect to stromal development (M Koller et al, manuscript in preparation). Because of the lack of adherent stroma in CB cultures, the potential for adequate performance from serum-free media was assessed. Both StemPro-34 and X-VIVO 15 serum-free media were compared with serum-containing medium. Although Stem- Pro-34 signficantly outperformed X-VIVO 15, both resulted in cell and CFU-GM output that was less than one quarter of serum-containing control cultures ( Figure 6 ). LTC-IC output was also significantly lower at 30-40% of the serum-containing control. 
Endogenous growth factor mRNA in CB and BM cultures
Accessory cells within perfused BM cultures are known to produce a number of growth factors which likely improve culture performance. 16, 17, 43 Because the accessory cell composition of CB cultures is different from BM cultures (ie lacking an adherent stroma), the presence of mRNA encoding a number of growth factors was assessed by RT-PCR (Figure 7) . Surprisingly, transcripts for most growth factors tested (G-CSF, GM-CSF, IL-1␤, IL-6, LIF, KL, FL, Tpo, Growth factor mRNA in bone marrow and cord blood expansion cultures. Total RNA was isolated from day 6 BM and CB cultures.
RT-PCR reactions were performed with primers specific for each message (Table 1) . PCR products were separated on a 2% agarose gel and visualized by ethidium bromide staining. The results are representative of four donor BM cultures and three donor CB cultures.
TGF-␤, TNF-␣, and MIP-1␣) were detected in both BM and CB cultures throughout the 12-day culture period. In contrast, IL-11 was detected only in BM cultures whereas IL-3 was not detected in either system. Although KL message was detected in both CB and BM, the ratio of soluble (416 bp) to membrane-bound (330 bp) message appeared to be decreased in CB cultures, similar to the decreased ratio observed from PB cells. 44 As expected, negative control RT reactions performed in the absence of the RT enzyme did not result in detectable products with any of the primer pairs when used as a template in the PCR reactions (not shown).
Automated clinical-scale CB cell expansion
The small-scale experimental results allowed the selection of culture conditions for clinical-scale expansion of CB cells in the automated Aastrom CPS. Thawed CB cells from three donors were inoculated at an average of 1.2 ϫ 10 ) per clinical-scale device, and were cultured for 12 days with continuous perfusion in parallel with small-scale cultures. In the clinicalscale device, cells and CFU-GM were expanded an average of 3.9-fold and 298-fold, respectively (Table 2) . These data are consistent with the parallel small-scale culture data, indicating that the perfusion culture process was scaled-up without loss of productivity. These experiments showed that a relatively small inoculum of thawed CB cells could be used to generate, on average, 4.4 ϫ 10 8 cells, 1.7 ϫ 10 7 CFU-GM, and 4.6 ϫ 10 3 LTC-IC in a single clinicalscale device.
Analysis of donor-to-donor variability
Over the course of these experiments, 10 CB samples were processed and expanded under a standard set of small-scale Table 2 Clinical-scale expansion of CB cells in the automated Aastrom cell production system Whole CB was cryopreserved and thawed, and then expanded using the small-scale and automated clinical-scale culture systems in parallel. Experiments 1, 2 and 3 were initiated with inoculum densities of 1.6 ϫ 10 5 , 1.8 ϫ 10 5 , and 1.3 ϫ 10 5 thawed viable nucleated cells per cm 2 , respectively. ND = not determined. culture conditions employing 3 ϫ 10 5 cells per cm 2 with medium perfusion for 12 days (Figure 8 ). Culture output was remarkably consistent from donor-to-donor, covering a 0.3-log range in cell output (coefficient of variation, C v = 0.31), a 0.4-log range in CFU-GM output (C v = 0.35), and a 1.0-log range in LTC-IC output (C v = 0.70). CFU-GM expansion ratios were somewhat more variable covering the range from 48-to 309-fold, with a mean value of 126-fold.
Experiment
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Discussion
The utilization of CB holds great promise as an alternative cell source for stem cell transplantation as well as other new procedures such as ex vivo gene therapy. However, as experience accumulates in the clinical setting, limitations for the more widespread application of CB are emerging. One limitation is the low number of cells available from most cryopreserved CB samples. This low cell number may contribute to delayed engraftment of neutrophils and platelets, 3,5 and may limit the general use of CB transplantation in adults and large pediatric patients. 6, 7 The use of ex vivo cell expansion has been proposed to overcome these potential limitations in CB transplantation. In addition, the successful expansion of CB cells would likely allow the use of smaller CB samples, thereby increasing the available donor pool and facilitating the use of better HLA-matched samples for many transplants.
For adult BM cell expansion, a perfusion culture technique has been previously developed and optimized, 20, 22, 23, 27 and the technique has since been implemented at the clinical-scale in a novel, automated cell production system (CPS). 30 The CPS has been used to generate patientspecific expanded BM cells used to augment normal BM transplantation, 24, 25 and as the sole means of hematopoietic support following cytoablative chemotherapy in breast cancer patients. 26 The current study addressed the optimization of the perfusion culture technique for the expansion of CB cells, and its subsequent clinical-scale implementation in the CPS.
The expansion of cells from cryopreserved and thawed CB samples was found to be enhanced through the use of frequent medium exchange or perfusion. Interestingly, CB cultures initiated over a wide range of inoculum densities were relatively insensitive to variations in the medium perfusion rate, a result that contrasts with BM cultures. 20 This difference is likely due to the lack of stromal formation in CB cultures, because much of the effect of medium perfusion has been shown to be stromal cell-mediated. 17 Nevertheless, the high density of non-stromal accessory cells present in the CB cultures did benefit from medium perfusion. These accessory cells are likely important for the endogenous production of many growth factors, as is the case in perfusion BM cultures. 17, 43 Despite the lack of adherent stroma, CB cultures, like BM cultures, expressed mRNA for a wide variety of important growth factors. The most significant difference between BM and CB cultures was the lack of IL-11 transcripts in CB cultures. This novel observation forms the basis for further investigations regarding the effect of IL-11 on CB expansion. Previous studies on CB cell growth factor expression have shown that CD34 ϩ CD45RA lo CD71 lo cell cultures express IL-1␤ mRNA, 45 and that stimulated MNC can be induced to express mRNA for a number of growth factors including G-CSF, GM-CSF, M-CSF, MIP-1␣ and TGF-␤, although transcript levels were often found to be less than levels from stimulated adult PB MNC. 46, 47 The issue of inoculum density is particularly important for CB due to the potential limitation of cells in the clinical setting. As inoculum density was increased, culture output increased, although in a significantly non-linear fashion. This resulted in lower cell and CFU-GM expansion ratios at both the lowest and highest inoculum densities, although total culture output was greatest at the higher inoculum densities. The maximization of expansion ratio vs the maximization of total culture output is an important balance to strike, because the competing objectives of providing a sufficient cell dose, but from the smallest possible inoculum, are both very compelling.
The clinical-scale CPS results indicate that Ͼ10 7 CFU-GM can be generated from a relatively small inoculum of approximately 10 8 thawed viable nucleated cells which is easily obtained from Ͻ15 ml of CB, representing Ͻ20% of the cells available from a typical CB sample.
3 This expanded CFU-GM dose is approximately 10-fold greater than that typically used in CB transplantation, 3 and might be beneficial for accelerating engraftment when given in an augmentation setting along with unmanipulated cells from the same sample. In order to implement this approach, it would be necessary to aliquot a small fraction of each CB sample prior to cryopreservation. Alternatively, the entire CB sample could be expanded and used for transplant, as has been done with adult BM. 26 Although some recent literature suggests that progenitor dose is not necessarily predictive of short-term engraftment potential, 48, 49 other studies have shown that cells at different stages of differentiation contribute to engraftment over different time scales in vivo in both mice [50] [51] [52] and humans. 53 Further, other studies have shown that ex vivo expanded cells can accelerate engraftment in mice. 52, [54] [55] [56] Ultimately, the clinical utility of expanded CB cells can only be resolved through human clinical trials designed to test their safety and efficacy. The simplicity of operation and closed-system design of the CPS offer significant advantages over manual culture techniques and will enable clinical studies to test the efficacy of expanded CB cells in the transplant setting.
Although GVHD has not been a major limitation in CB transplantation to date, some severe reactions have occurred, 2,3,5 and the incidence of GVHD might be expected to increase as more adults are transplanted. Flow cytometric analysis indicated a significant reduction in T and B lymphocytes during the expansion procedure, and this may be of potential benefit in the reduction of GVHD.
Despite the success of serum-free media formulations in CD34-enriched cell culture, 10 serum-free media are not generally used in accessory cell-containing cultures, likely due to the lack of support for BM stromal cell populations (M Koller et al, manuscript in preparation). Unlike BM cells, CB cells in vivo do not proliferate in association with an adherent stromal cell population, and therefore might not be expected to be as dependent on stroma as has been shown for BM cells. 17 In fact, CD34 ϩ CD38 Ϫ cells from CB are reported to be less dependent on stroma than CD34 ϩ CD38 Ϫ cells from BM. 14 Nevertheless, the two commercial serum-free media supported less than one quarter the level of culture output with serum-containing medium, perhaps due to the support by serum of high density non-stromal accessory cell populations which were present in these cultures.
Many studies have suggested that CB cells are more primitive than BM or mPB cells by in vitro proliferative measures. 8, [10] [11] [12] It has also been shown that the mean telomere length, a putative indicator of cellular proliferative history, is longer in CB cell populations than in BM cells. 13 Furthermore, long-term human cell engraftment in xenogeneic transplant models has been more successfully achieved with CB than with BM cell populations. 15 Finally, gene transduction protocols have been more successful with CB cells than with BM or mPB cells. 9 In the current study, CFU-GM expansion (126-fold) obtained with CB cells at an inoculum density of 3 ϫ 10 5 per cm 2 was significantly greater than that obtained with adult BM cells (13-fold) under identical culture conditions. 27 These different lines of evidence indicate that CB cell populations are significantly more primitive and have more in vitro and in vivo proliferative potential than BM or mPB cells. The ability to effectively manipulate and expand CB cells ex vivo offers a significantly improved opportunity for the successful implementation of a number of cell and gene therapy 57 protocols.
The data presented indicate that the perfusion culture technique was robust, yielding significant expansion from all donor samples tested, and resulted in a predictable output dose of cells, CFU-GM and LTC-IC. The level of reproducibility with CB was better than that obtained with adult BM MNC in terms of CFU-GM output (C v 0.35 vs 0.50) and LTC-IC output (C v 0.70 vs 1.08), and this was considerably better than the greater variability observed from BM CD34-enriched cell expansion. 58 It is uncertain whether donor-to-donor variability is due to genetic factors, or to other factors such as donor health, history or aspiration technique. Because CB is collected rather easily without aspiration or mobilization, the effect of collection technique is minimized. Further, the effect of donor health or history may also be minimized in these neonatal cell sources. Therefore, the donor-to-donor variability in CB cell expansion may give a more accurate assessment of the role of genetic factors on this phenomenon.
